Explore

Trendline Trendline
Eli Lilly Reenters Infectious Disease Market with $3.8 Billion Acquisitions

Eli Lilly Reenters Infectious Disease Market with $3.8 Billion Acquisitions

Eli Lilly Reenters Infectious Disease Market with $3.8 Billion Acquisitions
Trendline Trendline
Eli Lilly Acquires Three Vaccine Developers to Enhance Infectious Disease Prevention

Eli Lilly Acquires Three Vaccine Developers to Enhance Infectious Disease Prevention

Eli Lilly Acquires Three Vaccine Developers to Enhance Infectious Disease Prevention
Trendline Trendline
Eli Lilly Acquires Three Vaccine Developers to Boost Infectious Disease Prevention

Eli Lilly Acquires Three Vaccine Developers to Boost Infectious Disease Prevention

Eli Lilly Acquires Three Vaccine Developers to Boost Infectious Disease Prevention
Trendline Trendline
Eli Lilly Acquires Three Biotech Firms for $3.8 Billion to Boost Vaccine Development

Eli Lilly Acquires Three Biotech Firms for $3.8 Billion to Boost Vaccine Development

Eli Lilly Acquires Three Biotech Firms for $3.8 Billion to Boost Vaccine Development
Trendline Trendline
Eli Lilly Acquires Three Companies to Enhance Infectious Disease Portfolio

Eli Lilly Acquires Three Companies to Enhance Infectious Disease Portfolio

Eli Lilly Acquires Three Companies to Enhance Infectious Disease Portfolio
Trendline Trendline
Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference in New York

Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference in New York

Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference in New York
Trendline Trendline
Olympus Acquires Israeli Medtech Firm BioProtect in $270 Million Deal

Olympus Acquires Israeli Medtech Firm BioProtect in $270 Million Deal

Olympus Acquires Israeli Medtech Firm BioProtect in $270 Million Deal
Reuters Reuters
US FDA advisers to weigh updating 2026-27 COVID vaccines to target XFG variant

US FDA advisers to weigh updating 2026-27 COVID vaccines to target XFG variant

May 26 (Reuters) - Advisers to the U.S. Food and Drug Administration will discuss whether COVID-19 vaccines should be updated to target the latest circulating XFG subvariant for the 2026-27 immunization campaign, according to documents filed on Tuesday.
Trendline Trendline
MedTherapy Expands CAR-T Manufacturing in India to Reduce Costs and Increase Accessibility

MedTherapy Expands CAR-T Manufacturing in India to Reduce Costs and Increase Accessibility

MedTherapy Expands CAR-T Manufacturing in India to Reduce Costs and Increase Accessibility
Trendline Trendline
Verastem Oncology to Present at Jefferies Healthcare Conference 2026

Verastem Oncology to Present at Jefferies Healthcare Conference 2026

Verastem Oncology to Present at Jefferies Healthcare Conference 2026
Trendline Trendline
Kura Oncology's New Cancer Drug Shows Promise, Potential $2 Billion Market Opportunity

Kura Oncology's New Cancer Drug Shows Promise, Potential $2 Billion Market Opportunity

Kura Oncology's New Cancer Drug Shows Promise, Potential $2 Billion Market Opportunity
Trendline Trendline
PharmaEssentia to Present New Data on Ropeginterferon Alfa-2b for Essential Thrombocythemia at ASCO and EHA 2026

PharmaEssentia to Present New Data on Ropeginterferon Alfa-2b for Essential Thrombocythemia at ASCO and EHA 2026

PharmaEssentia to Present New Data on Ropeginterferon Alfa-2b for Essential Thrombocythemia at ASCO and EHA 2026